

Flash note 11/11/2020

Alex Fusté

@AlexfusteAlex alex.fuste@andbank.com

Russia says its Sputnik V COVID-19 vaccine is 92% effective. Lack of market reaction

- RDIF head Kirill Dmitriev, said just 1h ago today that its Sputnik V COVID-19 vaccine is 92% effective. Results are the second to be published from a late-stage human trial.
- The lack of market reaction highlights an element of mistrust, and this is perfectly justifiable. It is evident that vaccines will need to come from a more reliable source. Simply put, markets are ignoring any Russian vaccine news since most people don't trust Moscow.
- The analysis with the Sputnik vaccine was conducted after (just) 20 participants in the trial developed COVID virus and then examined how many had received the vaccine versus a placebo. That is significantly lower than the 94 infections in the trial of a vaccine being developed by Pfizer and BioNTech
- It is increasingly clear that investor's faith is in Pfizer, AstraZeneca or other big pharma names, with strong trial's design an protocols.
- All said, the Russian trial will continue for six more months and data from the study will also be published in a leading international medical journal.

El presente documento ha sido elaborado por Andbank, principalmente para su distribución interna y para inversores profesionales. La información en él contenida no debe considerarse un asesoramiento en materia de inversión ni una recomendación para la compra de activos o productos o la adopción de estrategias. Ninguna referencia a cualesquiera emisores de títulos o a cualesquiera valores que figuren en este documento se entenderá que constituye una recomendación de compra o de venta de tales valores.